Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Trial Profile

A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Atezolizumab (Primary) ; Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
  • Indications Carcinoma; Cervical cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
  • Focus Adverse reactions
  • Sponsors Gradalis
  • Most Recent Events

    • 07 Jan 2019 Planned End Date changed from 1 Apr 2019 to 1 Dec 2019.
    • 07 Jan 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top